Rifaximin
- Generic Name
- Rifaximin
- Brand Names
- Xifaxan, Zaxine
- Drug Type
- Small Molecule
- Chemical Formula
- C43H51N3O11
- CAS Number
- 80621-81-4
- Unique Ingredient Identifier
- L36O5T016N
- Background
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalop...
- Indication
Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in ...
- Associated Conditions
- Bacterial Infections, Clostridium difficile infection recurrence, Hepatic Encephalopathy (HE), Irritable Bowel Syndrome (IBS), Traveler's Diarrhea
- Associated Therapies
- -
A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy
- First Posted Date
- 2006-03-01
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 299
- Registration Number
- NCT00298038
Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome
- Conditions
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 525
- Registration Number
- NCT00269412
- Locations
- 🇺🇸
Gastroenterology Associates of Fairfield County, Bridgeport, Connecticut, United States
🇺🇸Litchfield County Gastroenterology Associates, LLC, Torrington, Connecticut, United States
🇺🇸University Clinical Research, DeLand, Florida, United States
Rifaximin for the Treatment of Irritable Bowel Syndrome
- Conditions
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2008-03-18
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 92
- Registration Number
- NCT00259155
Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea
- Conditions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2006-05-09
- Lead Sponsor
- DuPont, Hurbert L., MD
- Target Recruit Count
- 220
- Registration Number
- NCT00098384
- Locations
- 🇲🇽
Universidad Autonoma de Guadalajara, Guadalajara, Jalisco, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.